ArticleAnnals of hematology2026
MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) associated with PDGFRB rearrangements represent a rare but clinically significant category of hematologic malignancies, characterized by clonal eosinophilia and exceptional sensitivity to tyrosine kinase inhibitors. Among these, the MPRIP::PDGFRB fusion is exceptionally uncommon, with only three patients previously reported. Here, we report the first United States patient with MPRIP::PDGFRB fusion in a 34-year-old man presenting with leukocytosis, marked eosinophilia, anemia, thrombocytopenia, mucocutaneous lesions, hepatosplenomegaly, chronic gastrointestinal symptoms, and tree-in-bud pulmonary nodularity. Bone marrow evaluation revealed a markedly hypercellular marrow with increased eosinophils, grade 1 reticulin fibrosis, and dysmegakaryopoiesis. Fluorescence in situ hybridization (FISH) demonstrated a PDGFRB rearrangement in 76% of cells, and chromosome analysis revealed a balanced translocation t(5;17)(q32;p11.2). Next-generation sequencing RNA-based myeloid fusion panel analysis identified an MPRIP::PDGFRB fusion formed by an in-frame junction of MPRIP exon 20 and PDGFRB exon 12. The patient was initiated on imatinib therapy and achieved rapid remission. To contextualize this patient, we compared the clinical and molecular features of all previously published patients with MPRIP::PDGFRB fusion, noting shared findings of marked eosinophilia and excellent imatinib sensitivity, but notable heterogeneity in symptom burden, degree of marrow fibrosis, and associated immune-related manifestations. Additionally, we provide an overview of 45 reported PDGFRB fusion partner genes, summarizing their cytogenetic characteristics, and associated diseases. This case report expands the clinical spectrum of MPRIP::PDGFRB positive MLN-eo and underscores the essential role of cytogenetic and molecular testing in the diagnostic evaluation of eosinophilia, given the significant therapeutic implications of identifying PDGFRB fusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.